A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors
| Autor: | Eileen M. O'Reilly, Gerhard Frey, Jordi Rodon Ahnert, Matthew H. Taylor, Jingsong Zhang, Howard A. Burris, William J. Boyle, Michael Melnick, Wei Chen, Cathy Chang, Jay M. Short, Leslie L. Sharp, Yong Ben, Robert C. Doebele |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research Chemotherapy AXL receptor tyrosine kinase business.industry medicine.drug_class medicine.medical_treatment Monoclonal antibody Targeted therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis medicine Dose escalation Cancer research In patient business |
| Zdroj: | Journal of Clinical Oncology. 36:TPS12126-TPS12126 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.tps12126 |
| Popis: | TPS12126Background: The AXL receptor tyrosine kinase is often highly expressed in certain cancers. AXL appears to sustain resistance to anticancer therapies including chemotherapy, targeted therapy... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|